|
WO2014068302A1
|
|
Extrinsic calibration of imaging sensing devices and 2d lidars mounted on transportable apparatus
|
|
GB201219850D0
|
|
Extrinsic calibration of imaging sensing devices and 2D lidars mounted on transportable apparatus
|
|
EP2728376A1
|
|
Extrinsic calibration of imaging sensing devices and 2D LIDARs mounted on transportable apparatus
|
|
GB201205895D0
|
|
Localising transportable apparatus
|
|
GB201118704D0
|
|
Cystic fibrosis treatment
|
|
EP2439684A2
|
|
Automated assessment of examination scripts
|
|
KR20130009751A
|
|
Synthesis of dgjnac from d-glucuronolactone and use to inhibit alpha-n-acetylgalactosaminidases
|
|
GB201016708D0
|
|
Educational apparatus
|
|
CA2783405A1
|
|
N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation
|
|
KR20120041175A
|
|
Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
|
|
KR20120059447A
|
|
Cholesterol level lowering liposomes
|
|
GB0913579D0
|
|
Catalst and process
|
|
GB0909694D0
|
|
Catalyst and process
|
|
EP2282723A2
|
|
Endoplasmic reticulum targeting liposomes
|
|
WO2008134265A2
|
|
Iminosugar for treatment of tumors
|
|
US2007224648A1
|
|
Methods and compositions for the diagnosis of treatment of type 2 diabetes
|
|
CN101351222A
|
|
Mannose immunogens for HIV-1
|
|
EP2058004A1
|
|
Mannose immunogens for HIV-1
|
|
US2005138692A1
|
|
Production of cancer-specific antibodies in plants
|
|
US2004110795A1
|
|
Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
|
